Enliven Therapeutics ELVN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $81.65M-4.7% | $85.86M+6.3% | $85.34M+9.5% | $88.37M+15.8% | $85.7M+17.9% | ||
| $34.14M+39.0% | $33.8M+42.2% | $26.93M+20.1% | $25.87M+21.7% | $24.56M+20.2% | ||
| $115.79M+5.0% | $119.66M+14.4% | $112.27M+11.8% | $114.24M+17.1% | $110.26M+18.4% | ||
| -$115.79M-5.0% | -$119.66M-14.4% | -$112.27M-11.8% | -$114.24M-17.1% | -$110.26M-18.4% | ||
| $17.01M+14.7% | $16.01M+7.5% | $15.11M+3.9% | $14M-1.4% | $14.84M+9.7% | ||
| $17.01M+10.2% | $15.96M+2.8% | $15.06M-0.7% | $14.03M-4.8% | $15.43M+14.3% | ||
| -$98.78M-4.2% | -$103.69M-16.5% | -$97.21M-14.1% | -$100.22M-21.0% | -$94.83M-19.1% | ||
| -$1.67+13.0% | -$1.86+1.6% | -$1.84+2.6% | -$2.00-4.2% | -$1.920.0% | ||
| -$115.59M-5.1% | -$119.4M-14.5% | -$111.97M-11.9% | -$113.93M-17.1% | -$109.95M-18.5% | ||
| -$115.79M-5.0% | -$119.66M-14.4% | -$112.27M-11.8% | -$114.24M-17.1% | -$110.26M-18.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Enliven Therapeutics profitable?
- Enliven Therapeutics is not currently profitable: it reported a net loss of $98.8M over the trailing twelve months.
- What is Enliven Therapeutics's earnings per share?
- Enliven Therapeutics's diluted EPS over the trailing twelve months is $-1.67.
- Where does Enliven Therapeutics's income statement data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.